Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice the first effects of Mounjaro within the opening days of treatment — reduced appetite and a stronger sense of fullness after eating are often the earliest signs. Meaningful weight loss, however, builds over weeks and months. Clinical trial data from the SURMOUNT-1 programme, published in the New England Journal of Medicine, showed that participants lost an average of around 20–21% of body weight over 72 weeks at the highest dose — results that accumulate gradually, not overnight. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial is the most detailed window we have into how tirzepatide's effects unfold over time. Across thousands of adults without diabetes, weight loss was measurable within the first four weeks at even the lowest active doses. The rate of loss then steepened as participants moved through the titration schedule (5mg, 7.5mg and beyond) before levelling into a more gradual decline at higher doses. This tells you something practically useful: the first pen is rarely where the dramatic change happens. The NHS patient information on tirzepatide reflects this, noting that treatment works best when continued alongside a reduced-calorie diet and increased physical activity throughout the full course.
What the data cannot predict is your individual curve. Some people report noticeable appetite suppression by day three; others need two or three weeks before they feel a meaningful shift. Both patterns appeared within the trial population, which is why treating SURMOUNT-1's averages as a personal forecast tends to lead to frustration.
There are two distinct types of effect worth separating in your mind. The first is pharmacological: tirzepatide is a dual GIP and GLP-1 receptor agonist that slows how quickly your stomach empties and signals fullness to the brain. That mechanism activates quickly. Many people find portion sizes that used to feel normal now feel like too much after just a few days. Nausea (one of the most commonly reported early experiences) is itself a sign the medicine is active, even if it is an unwelcome one. The NHS tirzepatide page lists nausea, indigestion and constipation among the most frequent early effects; they typically ease within days to two weeks as your body adjusts.
The second type of effect is weight change on the scale. That lags the pharmacological signal by design. A reduction in appetite translates into a calorie deficit, which translates into fat loss, but that process takes time to show on the scales, especially in the first few weeks when water retention can mask early progress. If you are wondering how long after taking Mounjaro you feel the effects, a simple habit that takes under a minute can help you track progress accurately: weigh yourself at the same time of day, in similar clothing, once a week rather than daily. Weekly averages smooth out the normal fluctuations that can make a week of genuine progress look like nothing has changed.
The period between the 8-week and 24-week mark is where clinical evidence and patient experience most often align. By this point, most people on a supervised titration schedule have moved above the starter dose and are at a dose with genuine therapeutic weight-loss effect. The SURMOUNT-1 data showed that the steepest rate of weight loss occurred roughly in the first 36 weeks before tapering, meaning the cumulative loss continues, but the pace of change that feels most dramatic tends to cluster in this middle period.
It is also worth knowing that a pause in visible progress is normal and does not mean the medicine has stopped working. Plateaus are a recognised feature of weight management at any point, including on medical treatment. If you have concerns about your response after several months at a stable dose, that conversation belongs with your prescriber, not with a dose increase you decide on yourself. For context on what the treatment costs as part of a private service, the Mounjaro price comparison page sets out what a transparent private prescription typically includes.
Several factors shape the individual timeline. Starting BMI matters: people with higher starting weights often see larger absolute losses but similar percentage trajectories to those in the NICE TA1026 recommended population. Adherence to dietary changes alongside treatment makes a material difference, the trial results were achieved with lifestyle support, not with tirzepatide alone. The dose you ultimately reach is significant too; the 15mg data is the most striking in the trial, but not everyone needs or tolerates that level, and lower doses still produce meaningful results.
Medical history plays a role. People with insulin resistance or type 2 diabetes may notice blood-sugar regulation improving even before weight loss is obvious on the scale. Sleep quality, stress and hormonal factors all interact with the medicine in ways that individual variation makes hard to predict from published averages alone. Our guide on how long it takes to feel the effects of Mounjaro explores these individual variables in more detail, and the clinical team at nume reviews your full picture (not just your BMI) before recommending a treatment plan, and the aftercare available seven days a week means you have somewhere to go with questions as your response unfolds. If you want to understand how quickly you feel the effects of Mounjaro based on the broader evidence, the Mounjaro treatment overview covers the mechanism and licensed schedule in more detail. Questions about how effects sustain beyond active treatment are addressed on our page about how long Mounjaro's effects last.
Mounjaro is a prescription-only medicine. A clinical assessment is required before you start, and the prescriber's review does not stop at sign-up, every repeat order at nume is individually reviewed. If you are ready to find out whether tirzepatide is clinically suitable for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.